rosiglitazone has been researched along with amg-837 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Belin, RM; Brooks, DA; Cannady, EA; Cardona, GR; Chen, K; Chen, Q; Chen, Y; Coffey, DS; Deeg, MA; Eessalu, TE; Ficorilli, JV; Haas, JV; Hamdouchi, C; Johnson, JT; Kahl, SD; Lineswala, JP; Ma, X; Maiti, P; Marcelo, MC; Montrose-Rafizadeh, C; Otto, KA; Patel Lewis, A; Piper, JL; Pratt, EJ; Reifel Miller, A; Sweetana, SA; Wilbur, KL; Yumibe, NP; Zink, RW | 1 |
Deng, F; Li, Y; Li, Z; Zhang, D; Zhang, L; Zhou, Z | 1 |
2 other study(ies) available for rosiglitazone and amg-837
Article | Year |
---|---|
The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Discovery; Glucose Tolerance Test; HEK293 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Molecular Structure; Piperidines; Rats; Rats, Zucker; Receptors, G-Protein-Coupled; Spiro Compounds; Structure-Activity Relationship | 2016 |
Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARĪ³ and PPARĪ“.
Topics: Animals; CHO Cells; Cricetulus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Design; Glucose Tolerance Test; HEK293 Cells; Hep G2 Cells; Humans; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Mice, Obese; Models, Molecular; Molecular Structure; PPAR delta; PPAR gamma; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2018 |